Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC)
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …

Simple Summary Clear cell renal cell carcinomas (ccRCC) have several distinct
immunological features, including a high degree of immune infiltration and relatively low …

Regulatory T (Treg) cells are one of the major immunosuppressive cell types in cancer and a
potential target for immunotherapy, but targeting tumor-infiltrating (TI) Treg cells has been …

Immunotherapy treatments harnessing the immune system herald a new era of personalized
medicine, offering considerable benefits for cancer patients. Over the past years, tumor …

Posttranslational modifications (PTMs), such as phosphorylation, methylation, ubiquitination,
and acetylation, are important in governing protein expression levels. Proteolysis targeting …

Pancreatic cancer is the third most common cause of cancer-related deaths in the United
States. Although gemcitabine is the standard of care for most patients with pancreatic …

Cellular senescence plays a crucial role in tumorigenesis, development and immune
modulation in cancers. However, to date, a robust and reliable cellular senescence-related …

Lysosome-targeting chimeras (LYTACs) offer an opportunity for the degradation of
extracellular and membrane-associated proteins of interest. Here, we report an efficient …

Apoptosis is the major mode of programmed cell death, which conduces to maintain tissue
homeostasis, clearance of abnormal cells and development of organisms. Over the past two …

The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality
with the promise to tame disease-relevant proteins in ways that are difficult or impossible to …